Experimental spinal fusion with recombinant human bone morphogenetic protein-2 without decortication of osseous elements

被引:92
作者
Sandhu, HS
Kanim, LEA
Toth, JM
Kabo, JM
Liu, D
Delamarter, RB
Dawson, EG
机构
[1] UNIV CALIF LOS ANGELES,SCH MED,UCLA COMPREHENS SPINE CTR,LOS ANGELES,CA 90095
[2] MED COLL WISCONSIN,DEPT ORTHOPAED SURG,MILWAUKEE,WI 53226
关键词
bone induction; bone morphogenetic protein; canine; decortication; polylactic acid polymer; posterolateral fusion; recombinant bone morphogenetic protein-2; spine fusion technique;
D O I
10.1097/00007632-199706010-00001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Design. L4-L5 intertransverse process fusions were produced with 58 mu g, 230 mu g, or 920 mu g of recombinant human bone morphogenetic protein-2 in 20 dogs. Eleven had traditional decortication of posterior elements before insertion of the implant. Nine were left undecorticated. All animals were evaluated 3 months after surgery. Objectives. To determine whether decortication is a prerequisite for successful fusion in the presence of osteoinductive proteins such as bone morphogenetic protein-2. Summary of Background Data. Recombinant osteoinductive proteins can induce de novo bone in ectopic soft-tissue sites in the absence of bone marrow elements. Traditional methods for achieving spinal fusion rely on exposure of bone marrow through decortication to facilitate osteogenesis. It is hypothesized that the presence of an implanted osteoinductive protein obviates the need for exposure and release of host inductive factors. Methods. Recombinant human bone morphogenetic protein-2-induced intertransverse process fusions were performed with and without decortication. Fusion sites were evaluated by computed tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic analysis. Results. One hundred percent of decorticated spines and 89% of undecorticated spines were clinically fused by 3 months. Ninety-one percent of decorticated spines and 78% of undecorticated specimens exhibited bilateral transverse process osseous bridging. The only spines that failed to achieve solid bilateral arthrodesis were in the lowest dose group. With the higher two doses, there was histologic evidence of osseous continuity between the fusion mass and undecorticated transverse processes. Conclusions. There were no statistical differences in clinical and radiographic fusion rates between decorticated and undecorticated sites. With higher doses of recombinant human bone morphogenetic protein-2, there was little histologic distinction between fusions in decorticated versus undecorticated spines.
引用
收藏
页码:1171 / 1180
页数:10
相关论文
共 50 条
  • [11] Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2
    Villavicencio, AT
    Burneikiene, S
    Nelson, EL
    Bulsara, KR
    Favors, M
    Thramann, J
    JOURNAL OF NEUROSURGERY-SPINE, 2005, 3 (06) : 436 - 443
  • [12] Changes in Recombinant Human Bone Morphogenetic Protein-2 Use in Posterior Fusion Over the Past Two Decades
    Nabizadeh, Naveed
    Glassman, Steven D.
    Djurasovic, Mladen
    Crawford, Charles H.
    Gum, Jeffrey L.
    Carreon, Leah
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [13] A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats
    Miyazaki, Masashi
    Morishita, Yuichiro
    He, Wubing
    Hu, Ming
    Sintuu, Chananit
    Hymanson, Henry J.
    Falakassa, Jonathan
    Tsumura, Hiroshi
    Wang, Jeffrey C.
    SPINE JOURNAL, 2009, 9 (01) : 22 - 30
  • [14] A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration
    Yokota, S
    Sonohara, S
    Yoshida, M
    Murai, M
    Shimokawa, S
    Fujimoto, R
    Fukushima, S
    Kokubo, S
    Nozaki, K
    Takahashi, K
    Uchida, T
    Yokohama, S
    Sonobe, T
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 223 (1-2) : 69 - 79
  • [15] Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy
    Alden, TD
    Pittman, DD
    Beres, EJ
    Hankins, GR
    Kallmes, DF
    Wisotsky, BM
    Kerns, KM
    Helm, GA
    JOURNAL OF NEUROSURGERY, 1999, 90 (01) : 109 - 114
  • [16] Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear
    Glassman, Steven D.
    Gum, Jeffrey L.
    Crawford, Charles H., III
    Shields, Christopher B.
    Carreon, Leah Y.
    SPINE JOURNAL, 2011, 11 (06) : 522 - 526
  • [17] Use of Recombinant Human Bone Morphogenetic Protein-2 in the Treatment of Degenerative Spondylolisthesis
    Schroeder, Gregory D.
    Hsu, Wellington K.
    Kepler, Christopher K.
    Kurd, Mark F.
    Vaccaro, Alexander R.
    Patel, Alpesh A.
    Savage, Jason W.
    SPINE, 2016, 41 (05) : 445 - 449
  • [18] Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein-2
    O'Shaughnessy, Brian A.
    Kuklo, Timothy R.
    Ondra, Stephen L.
    SPINE, 2008, 33 (05) : E132 - E139
  • [19] Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2
    Lu, Sheldon X.
    Fiorini, Tiago
    Lee, Jaebum
    Prasad, Hari S.
    Buxton, Amanda N.
    Bisch, Fredrick C.
    Dixon, Douglas R.
    Susin, Cristiano
    Wikesjoe, Ulf M. E.
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2013, 40 (07) : 688 - 697
  • [20] The effects of heat on the biological activity of recombinant human bone morphogenetic protein-2
    Ohta, H
    Wakitani, S
    Tensho, K
    Horiuchi, H
    Wakabayashi, S
    Saito, N
    Nakamura, Y
    Nozaki, K
    Imai, Y
    Takaoka, K
    JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (06) : 420 - 425